posted
Nice call TEX, IYXI is up 25% from where you spotted it...That's what this thread is all about Posts: 2383 | Registered: Apr 2006
| IP: Logged |
posted
ESI Announces Fiscal 2007 Fourth Quarter and Year-End Results with Strongest Fiscal Year since 2001 Thursday July 12, 4:05 pm ET
PORTLAND, Ore.--(BUSINESS WIRE)--Electro Scientific Industries, Inc. (NASDAQ:ESIO - News), a leading provider of world-class photonic and laser micro-engineering systems, today announced results for its fiscal 2007 fourth quarter ended June 2, 2007.
posted
LifeVantage Corporation Obtains Patent for Science-Based Dietary Supplement Product Thursday July 12, 6:17 pm ET
GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--LifeVantage Corporation (OTCBB: LFVN - News), formerly Lifeline Therapeutics, Inc., maker of Protandim®, today announced a patent was granted on July 10, 2007 for its antioxidant therapy formula used in Protandim®. The patent, titled "Compositions for Alleviating Inflammation and Oxidative Stress in a Mammal," is the first patent granted to LifeVantage Corporation. Two other patent applications have been filed by LifeVantage for Protandim®-based science. ADVERTISEMENT
Dr. Joe McCord, LifeVantage's Director of Science and co-discoverer of the important antioxidant enzyme superoxide dismutase, stated, "The issuance of this first U.S. patent underscores the unique nature of Protandim®'s approach to antioxidant therapy, and the remarkable synergy of its five phytochemical components working together. We believe this adds substantial validation to the science that has led to the creation of Protandim®."
James J. Krejci, CEO of LifeVantage, added, "This patent reinforces LifeVantage's approach to developing science-based, natural solutions that deliver significant health benefits to our customers in helping them reach their health and wellness goals. The patent, which is the basis of the Protandim® formula, also provides conclusive evidence to our customers, retail partners, and healthcare professionals that they have chosen a proven solution in reducing oxidative stress and supporting healthy aging."
About Protandim®
Protandim® is a unique approach to antioxidant therapy. The patent-pending dietary supplement increases the body's natural antioxidant protection by inducing naturally occurring protective enzymes, including superoxide dismutase (SOD) and catalase (CAT). Oxidative stress occurs as a person ages, when subjected to environmental stresses, or as an associated factor in certain illnesses. TBARS are laboratory markers for oxidative stress in the body. Data from a scientific study in men and women, sponsored by LifeVantage, show that after 30 days of taking Protandim®, the level of circulating TBARS decreased an average of 40 percent. With continued use, the decrease was maintained at 120 days. For more information, please visit www.protandim.com.
About LifeVantage Corporation
LifeVantage Corporation is committed to helping people achieve health and wellness for life. For more information, please visit the Company's web site at www.LifeVantage.com.
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company uses the words "anticipate," "believe," "could," "should," "estimate," "expect," "intend," "may," "predict," "project," "plan," "target" and similar terms and phrases, including references to assumptions, to identify forward-looking statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, the risk that government regulators and regulations could adversely affect our business; future laws or regulations may hinder or prohibit the production or sale of our existing product and any future products; unfavorable publicity could materially hurt our business; and the Company's ability to protect our intellectual property rights and the value of our product. These and other risk factors are discussed in greater detail in the Company's Annual Report on Form 10-KSB under the caption "Risk Factors," and in other documents filed the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
Contact: LifeVantage Corporation James J. Krejci, CEO, 720-488-1711 Fax: 303-565-8700
Posts: 2383 | Registered: Apr 2006
| IP: Logged |
posted
Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 3454 Alzheimer's Disease Trial Thursday July 12, 4:10 pm ET
MONTVALE, N.J., July 12 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced that it has completed enrollment in its Phase 2a trial of MEM 3454, the company's lead nicotinic alpha-7 receptor partial agonist, in Alzheimer's disease. The Company expects to report top- line results for this trial in the fourth quarter of 2007. ADVERTISEMENT
"The rapidity with which we were able to complete enrollment of this study, along with our recent announcement that we are planning to initiate a proof-of-concept study in cognitive impairment associated with schizophrenia (CIAS), underlines the enthusiasm we, our investigators and our partner Roche have for MEM 3454," said Stephen R. Murray, M.D., Ph.D., Vice President of Clinical Development. "We are pleased to have completed the trial's enrollment in just a few months, remaining on track to share top-line data from two Phase 2a trials - MEM 3454 in Alzheimer's disease and MEM 1003 in Alzheimer's disease - in the fourth quarter of this year."
The Phase 2a trial is a randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability and cognitive effects of three doses of MEM 3454. The trial enrolled approximately 80 subjects with mild to moderate Alzheimer's disease at multiple sites in the United States. Subjects in the study were randomized at enrollment to receive 5 mg, 15 mg or 50 mg of MEM 3454 or placebo once daily for a period of eight weeks. The primary objective of the trial is to assess the effect of MEM 3454 using the Quality of Episodic Secondary Memory (QESM) factor score from the Cognitive Drug Research (CDR) battery. Secondary objectives include assessing the safety, tolerability, and pharmacokinetics of multiple doses of MEM 3454 and the drug candidate's effect on additional psychometric test items from the CDR battery and the Alzheimer's Disease Assessment Scale -- Cognitive subscale.
MEM 3454 is a partial agonist of the nicotinic alpha-7 receptor, a highly specialized receptor found in the central nervous system (CNS). Compounds acting on this receptor could be beneficial in the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders.
About the Company
Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders such as Alzheimer's disease, schizophrenia and depression. For additional information, please visit our website at http://www.memorypharma.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationship with Bayer; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; and protecting the intellectual property developed by or licensed to Memory Pharmaceuticals. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
quote:Originally posted by Happy Valley: LifeVantage Corporation Obtains Patent for Science-Based Dietary Supplement Product Thursday July 12, 6:17 pm ET
but we gotta watch it. Anybody who likes to gambol with da gamblers can buy now... Otherwise, guage everything *if* hits .0005 x .0006. Prolly will reach .0012 if so... plus, news *might* make it take off...
posted
Just watching this one on the short side - already had a nice dip in May but imo will have another dip considering recent news with Avandia ~ watching GSK. a bit pricy at 52.64 so I won't be getting in but thought I'd mention it. Since i accidentally typed in GSX i'm checking that one out also lol.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
DRI Corporation Announces Preliminary Second Quarter Results Friday July 13, 8:30 am ET -- Second Quarter Sales Reach Record High -- Second Quarter Results Mark Seventh Period of Consecutive Improvement -- Friedland Conference (Atlantic City) Participation Slated on July 16 at 11 a.m. (Eastern) to Help Increase Public Awareness
DALLAS--(BUSINESS WIRE)--DRI Corporation (formerly known as Digital Recorders, Inc.) (DRI) (NASDAQ: TBUS - News), a digital communications technology leader in the domestic and international surface transportation and transit security markets, announced today that second quarter sales are expected to exceed approximately $14.5 million, as compared to $13.6 million posted for the same period a year ago
posted
GS Carbon Executes Agreement to Acquire Majority Stake of WiseBuys Stores, Inc. Friday July 13, 8:00 am ET
NEW YORK--(BUSINESS WIRE)--GS Carbon (OTC Bulletin Board: GSCR - News) today announced it has recently executed a number of share purchase agreements to acquire preferred and common stock of WiseBuys Stores, Inc. that equate to an approximate 60% voting stake in the company. The transaction is contingent upon completion of audited financials for WiseBuys.
Topic Closed
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Wink]](wink.gif)
![[Smile]](smile.gif)
